On August 23, 2019, Illinois governor J.B. Pritzker signed House Bill 3113 into law, effective January 1, 2020.1 The Viewpoint by Adamson and Pignone,2 published in this issue of JAMA Dermatology, presents the authors’ considerations of the potential harms of this new bill, which was first published online during the 60-day consideration period prior to the governor’s signing. Eliminating copayments for routine skin cancer screening may have a significant effect on individual patients, access to dermatologic care, and the health care system at large. The expected, as well as unanticipated, consequences of this cost-sharing measure should be evaluated and measured by dermatologists and health policy experts to better understand the effects of this law prior to expanded adoption by other states.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Shinkai K. Understanding the Consequences of Eliminating Copayments for Skin Cancer Screening. JAMA Dermatol. 2019;155(12):1341. doi:10.1001/jamadermatol.2019.3740
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: